Affymetrix to Webcast Presentation at the 2013 Leerink Swann Global Healthcare Conference
Affymetrix to Webcast Presentation at the 2013 Leerink Swann Global Healthcare Conference
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Affymetrix, Inc. (NAS: AFFX) today announced that it will webcast the Company's presentation at the Leerink Swann Global Healthcare Conference in New York City on Thursday, February 14, 2013. The live webcast is scheduled to begin at 3:00 p.m. ET and will feature a corporate overview and update by Tim Barabe, executive vice president and chief financial officer.
A live webcast will be available at http://www.affymetrix.com under the "Investors" link. The archived webcast will be available for 30 days.
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 2,300 systems have been shipped around the world and more than 48,000 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, and Singapore. eBioscience is headquartered in San Diego, California and has manufacturing facilities in San Diego and Vienna, Austria. Including eBioscience, the Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia and Latin America.
Affymetrix, Inc.
Doug Farrell, 408-731-5285
Vice President, Investor Relations
KEYWORDS: United States North America California New York
INDUSTRY KEYWORDS:
The article Affymetrix to Webcast Presentation at the 2013 Leerink Swann Global Healthcare Conference originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
